MTANZ

Select Relevant Account

Select yourself to see only your informmation.
Select an organisation to manage it as well.

Login





Forgot password?
Create an Account

In The News

News Diabetes scanning technology replaces pricking
25 May 2017
News Rex Bionics shareholders back lifeline deal
25 May 2017
News Mike Daniell joins board of Australasia’s largest life science venture capital fund.
17 May 2017
News TGA releases new clinical guidelines for Medical Devices and IVDs
31 Mar 2017
News Call from Health Minister for clinicians to share ‘disruptive’ ideas
27 Mar 2017
News EpiPen adrenaline auto-injectors recalled in NZ
23 Mar 2017
News Surgical Mesh - Media Release MTANZ
22 Mar 2017
News New Role for Dr Diana Siew to develop International Partnerhips
21 Mar 2017
News Samsung testing new heart monitor at Middlemore Hospital
03 Mar 2017
News MTAA appoints Ian Burgess as CEO
21 Dec 2016
News Molteno Ophthalmic Ltd changes lives
23 Jul 2016
News Pacific Edge and MKM Health win NZ Healthcare Awards
22 Jun 2016
News NZ Health Technology Review
22 Jun 2016
News Smart technology will transform NZ healthcare - Media Release MTANZ
15 Jun 2016
News New surgical scholarship program by RACS and Johnson & Johnson Medical
10 May 2016
News NZ Medical and Scientific introduces a Mobile Continuous Glucose Monitoring System
01 Mar 2016
PagePage12
 
Baxter Healthcare wins 2018 James & Wells MTANZ Innovation Award 20 Jun 2018

A new haemodialysis therapy that has the potential to significantly advance renal care for patients in New Zealand has won the James & Wells Medical Technology Association of New Zealand (MTANZ) Innovation Award for 2018.

Baxter Healthcare received the award for its HDx enabled by Theranova haemodialysis therapy from Jonathan Lucas, partner at James & Wells, at the Health Tech Week Gala Dinner.

Theranova is an innovative dialyser. It more closely mimics the natural kidney compared with other dialysis membranes. Theranova extends the range of toxins that can be filtered from the blood during haemodialysis for the first time without significant albumin loss.

This technology is unique in New Zealand and global markets. The therapy is designed to work with all haemodialysis machines. This allows clinics to offer HDx therapy using existing resources and staff.

“MTANZ believes these awards, which are open to both imported and locally developed medical technology, show the tremendous innovation in the NZ health technology market. Innovation is so essential to deliver better outcomes for patients and improve efficiencies in the NZ healthcare system,” says MTANZ chief executive Faye Sumner, CNZM.

Check out the Scoop article

TOP

©copyright Medical Technology Association of New Zealand, all rights reserved. Privacy Policy and Disclaimer.

Powered by streamSWEET CMS